Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients with Third-Line or Later (3L+) Follicular Lymphoma (FL) from TRANSCEND FL

Key Points

• Efficacy was measured by overall response rate, achieving 70% in the treatment group after three years.
• Safety assessments documented adverse events, with 20% of patients experiencing serious side effects.
• Analysis included patients who had previously failed multiple treatments, confirming liso-cel's role in their care.
• Findings imply that lisocabtagene maraleucel may offer lasting benefits, but further validation is essential.